Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxart, Inc.VXRT · Entity 6654 | SVP, Chief Scientific Officer | March 28, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxart, Inc.
Report date March 28, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 882,811 |
Reported balance
After 2026-03-28 transaction · row 1
1 source rowRow 1 · 2026-03-28 · Tax withholding · Disposed 3,924 · Balance 882,811 F1: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy joint tenancy with Frances Chang and Sean Tucker | 51,465 |
Reported balance
Holding disclosure · report date 2026-03-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 51,465 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 9,060 |
Reported balance
Holding disclosure · report date 2026-03-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 9,060 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2026 Filed Mar 31, 2026 20:44 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,924 | $0.65 | $2,550.60 |
DisclosureSEC source: 0001437749-26-010709 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 882,811 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. Read SEC document |
| March 24, 2026 Filed Mar 26, 2026 20:51 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 36,418 | $0.69 | $25,274.09 |
DisclosureSEC source: 0001437749-26-009966 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 886,735 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 19:14 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 8,072 | $0.63 | $5,122.49 |
DisclosureSEC source: 0001437749-26-009205 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923,153 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:42 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001437749-26-008909 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2036-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 23:42 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-008909 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 931,225 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 23:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 9,265 | $0.61 | $5,637.75 |
DisclosureSEC source: 0001437749-26-003253 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,225 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,913 | $0.42 | $1,648.16 |
DisclosureSEC source: 0001437749-25-010486 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 740,490 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2025. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 01:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 610,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001437749-25-009451 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,000 Underlying: Common Stock · 610,000 shares Expires 2035-03-24 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 24, 2026, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 24, 2029. Read SEC document |
| March 24, 2025 Filed Mar 27, 2025 01:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 406,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-009451 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,403 F1 · shares: Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 24, 2025, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 18, 2025 Filed Mar 21, 2025 01:27 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 8,050 | $0.57 | $4,590.11 |
DisclosureSEC source: 0001437749-25-008650 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,403 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2025. Read SEC document |
| February 02, 2025 Filed Feb 5, 2025 01:11 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 9,242 | $0.68 | $6,282.71 |
DisclosureSEC source: 0001437749-25-002803 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,453 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2025. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 23:16 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,902 | $1.30 | $5,072.60 |
DisclosureSEC source: 0001437749-24-010475 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,695 F1 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested on March 28, 2024. Read SEC document |
| March 18, 2024 Filed Mar 21, 2024 00:12 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001437749-24-008753 · rdgdoc.xml · derivative · entry 5 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2034-03-17 F6 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 18, 2025, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 18, 2028. Read SEC document |
| March 18, 2024 Filed Mar 21, 2024 00:12 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-008753 · rdgdoc.xml · nonDerivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,122 F5 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 18, 2024, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| February 02, 2024 Filed Mar 21, 2024 00:12 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 9,220 | $1.20 | $11,064.00 |
DisclosureSEC source: 0001437749-24-008753 · rdgdoc.xml · nonDerivative · entry 3 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,122 F1 · date: This transaction is being reported late due to administrative oversight. F4 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2024. Read SEC document |
| December 08, 2023 Filed Mar 21, 2024 00:12 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 34,288 | $0.71 | $24,344.48 |
DisclosureSEC source: 0001437749-24-008753 · rdgdoc.xml · nonDerivative · entry 2 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,342 F1 · date: This transaction is being reported late due to administrative oversight. F3 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of December 8, 2023. Read SEC document |
| March 28, 2023 Filed Mar 21, 2024 00:12 UTC | Vaxart, Inc. VXRT · Entity 6654 | Tax withholdingCommon Stock | 3,683 | $0.75 | $2,762.25 |
DisclosureSEC source: 0001437749-24-008753 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,630 F1 · date: This transaction is being reported late due to administrative oversight. F2 · shares: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 410,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · derivative · entry 7 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 410,000 shares Expires 2033-03-16 F4 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on February 2, 2024, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on February 2, 2027. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 205,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · derivative · entry 6 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2033-03-16 F2 · derivative.exercise_date: The shares subject to this stock option shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · nonDerivative · entry 3 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,788 F3 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the vesting commencement date of February 2, 2023, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 54,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · nonDerivative · entry 2 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,788 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 23:54 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007440 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,631 F1 · shares: Grant of shares upon vesting of restricted stock units, which shall fully vest on December 8, 2023. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:40 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001437749-22-009651 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,061 Underlying: Common Stock · 40,000 shares Expires 2029-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of May 10, 2019, and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 20:40 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionCommon Stock | 40,000 | $0.77 | $30,800.00 |
DisclosureSEC source: 0001437749-22-009651 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:19 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 262,500 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0001437749-22-007738 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2032-03-27 F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 28, 2023, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 28, 2026. Read SEC document |
| March 28, 2022 Filed Mar 31, 2022 01:19 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-007738 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,631 F1 · shares: Grant of shares upon vesting of restricted stock units. Twenty five percent of the shares underlying the award shall vest on each anniversary of the grant date, so that the restricted stock units would be fully vested on the fourth anniversary of the grant date. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | SaleCommon Stock | 5,828 | $10.20 | $59,445.60 |
DisclosureSEC source: 0001437749-21-019515 · rdgdoc.xml · nonDerivative · entry 2 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By joint tenancy with Frances Chang and Sean Tucker Disclosed balance after: 51,465 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:53 UTC | Vaxart, Inc. VXRT · Entity 6654 | SaleCommon Stock | 4,172 | $10.20 | $42,554.40 |
DisclosureSEC source: 0001437749-21-019515 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,881 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 20:23 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $6.27 | $0.00 |
DisclosureSEC source: 0001437749-21-015074 · rdgdoc.xml · derivative · entry 1 Tucker Sean · CIK 0001652204 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock · 100,000 shares Expires 2031-03-24 F1 · date: The option grant was approved by the board of directors of Vaxart, Inc. on March 25, 2021, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 16, 2021. F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 25, 2022, the first anniversary of the date that the grant was approved by the board of directors, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 25, 2025. Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 21:04 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionStock Option (right to buy) · Derivative | 1,006 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001437749-21-006473 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,006 shares Expires 2021-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested Read SEC document |
| March 16, 2021 Filed Mar 19, 2021 21:04 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionCommon Stock | 1,006 | $6.49 | $6,528.94 |
DisclosureSEC source: 0001437749-21-006473 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:21 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionStock Option (right to buy) · Derivative | 4,026 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001437749-20-018044 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,026 shares Expires 2020-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:21 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionCommon stock | 4,026 | $6.49 | $26,128.74 |
DisclosureSEC source: 0001437749-20-018044 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:38 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001437749-20-012741 · rdgdoc.xml · derivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2030-03-23 F1 · date: The option grant was approved by the board of directors of Vaxart, Inc. on March 24, 2020, subject to stockholder approval of an amendment to the Vaxart, Inc. 2019 Equity Incentive Plan, under which the stock option was granted. Vaxart, Inc.'s stockholders approved the plan amendment on June 8, 2020. F2 · derivative.exercise_date: The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on the date of grant, and thereafter in 24 equal monthly installments commencing on the first day of the calendar month following the grant date such that the stock option shall be fully vested on April 1, 2022. Read SEC document |
| May 12, 2019 Filed May 14, 2019 21:28 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 124,061 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001209191-19-029721 · doc4.xml · derivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,061 Underlying: Common Stock · 124,061 shares Expires 2029-05-11 F1 · derivative.exercise_date: The option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date of May 10, 2019, and the remaining shares subject to the option vesting in equal monthly installments over the next 36 months. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 22:04 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 27,273 | $1.10 Strike: $1.10 | $30,000.30 |
DisclosureSEC source: 0001437749-19-007119 · rdgdoc.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By joint tenancy with Frances Chang and Sean Tucker Disclosed balance after: 27,273 Underlying: Common Stock · 27,273 shares Expires 2024-04-11 F1 · price: Each share of common stock was purchased together with a common warrant to purchase one share of the Issuer's common stock at the combined purchase price of $1.10. The Reporting person may not exercise any portion of the common warrant to the extent that he would beneficially own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the Reporting Person to the Issuer, he may increase the amount of beneficial ownership of outstanding stock after exercising his common warrants up to 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 22:04 UTC | Vaxart, Inc. VXRT · Entity 6654 | PurchaseCommon stock | 27,273 | $1.10 | $30,000.30 |
DisclosureSEC source: 0001437749-19-007119 · rdgdoc.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By joint tenancy with Frances Chang and Sean Tucker Disclosed balance after: 52,661 F1 · price: Each share of common stock was purchased together with a common warrant to purchase one share of the Issuer's common stock at the combined purchase price of $1.10. The Reporting person may not exercise any portion of the common warrant to the extent that he would beneficially own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the Reporting Person to the Issuer, he may increase the amount of beneficial ownership of outstanding stock after exercising his common warrants up to 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. Read SEC document |
| May 25, 2018 Filed May 30, 2018 01:41 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001209191-18-034055 · doc4.xml · derivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-05-24 F1 · derivative.exercise_date: The shares subject to this Option shall vest as follows: 1/4th of the total number of shares subject to the Option shall vest on the day preceding the 12-month anniversary of the vesting commencement date of February 13, 2018 and 1/48th of the total number of shares subject to the Option shall vest on the day preceding each monthly anniversary of the vesting commencement date thereafter. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:11 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionStock Option (right to buy) · Derivative | 2,013 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001209191-18-019742 · doc4.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,013 shares Expires 2018-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:11 UTC | Vaxart, Inc. VXRT · Entity 6654 | Exercise / conversionCommon Stock | 2,013 | $6.49 | $13,064.37 |
DisclosureSEC source: 0001209191-18-019742 · doc4.xml · nonDerivative · entry 1 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Optin (right to buy) · Derivative | 9,060 | Not disclosed Strike: $4.07 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 12 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,060 Underlying: Common Stock · 9,060 shares Expires 2027-06-24 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F10 · price: On June 24, 2017, Reporting Person was granted an option to purchase 450,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.08 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,060 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $4.07 (as adjusted for the Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 14, 2017 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter. F10 · derivative.exercise_date: On June 24, 2017, Reporting Person was granted an option to purchase 450,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.08 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,060 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $4.07 (as adjusted for the Stock Split). The option vests with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of June 14, 2017 and with respect to the remaining shares underlying the option in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Optin (right to buy) · Derivative | 7,731 | Not disclosed Strike: $12.98 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 11 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,731 Underlying: Common Stock · 7,731 shares Expires 2026-03-25 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F9 · price: On March 25, 2016, Reporting Person was granted an option to purchase 384,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.26 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,731 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $12.98 (as adjusted for the Stock Split). The option vests in 48 equal monthly installments beginning from March 25, 2016. F9 · derivative.exercise_date: On March 25, 2016, Reporting Person was granted an option to purchase 384,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.26 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 7,731 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $12.98 (as adjusted for the Stock Split). The option vests in 48 equal monthly installments beginning from March 25, 2016. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 10,067 | Not disclosed Strike: $17.49 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 10 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,067 Underlying: Common Stock · 10,067 shares Expires 2025-07-23 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F8 · price: On July 23, 2015, Reporting Person was granted an option to purchase 500,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.35 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 10,067 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $17.49 (as adjusted for the Stock Split). The option vests in 48 equal monthly installments beginning from July 1, 2015. F8 · derivative.exercise_date: On July 23, 2015, Reporting Person was granted an option to purchase 500,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.35 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 10,067 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $17.49 (as adjusted for the Stock Split). The option vests in 48 equal monthly installments beginning from July 1, 2015. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 11,604 | Not disclosed Strike: $8.03 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 9 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,604 Underlying: Common Stock · 11,604 shares Expires 2024-05-08 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F7 · price: On May 8, 2014, Reporting Person was granted an option to purchase 576,338 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 11,604 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $8.03 (as adjusted for the Stock Split). This option is fully vested. F7 · derivative.exercise_date: On May 8, 2014, Reporting Person was granted an option to purchase 576,338 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 11,604 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $8.03 (as adjusted for the Stock Split). This option is fully vested. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 10,523 | Not disclosed Strike: $6.49 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 8 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,523 Underlying: Common Stock · 10,523 shares Expires 2023-08-08 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F6 · price: On August 8, 2013, Reporting Person was granted an option to purchase 522,676 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 10,523 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. F6 · derivative.exercise_date: On August 8, 2013, Reporting Person was granted an option to purchase 522,676 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 10,523 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 3,020 | Not disclosed Strike: $8.03 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 7 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,020 Underlying: Common Stock · 3,020 shares Expires 2022-04-13 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F5 · price: On April 13, 2012, Reporting Person was granted an option to purchase 150,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,020 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $8.03 (as adjusted for the Stock Split). This option is fully vested. F5 · derivative.exercise_date: On April 13, 2012, Reporting Person was granted an option to purchase 150,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.16 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 3,020 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $8.03 (as adjusted for the Stock Split). This option is fully vested. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 1,006 | Not disclosed Strike: $6.49 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 6 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006 Underlying: Common Stock · 1,006 shares Expires 2021-03-30 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F4 · price: On March 30, 2011, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 1,006 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. F4 · derivative.exercise_date: On March 30, 2011, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 1,006 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 4,027 | Not disclosed Strike: $6.49 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 5 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,027 Underlying: Common Stock · 4,027 shares Expires 2020-08-27 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F3 · price: On August 27, 2010, Reporting Person was granted an option to purchase 200,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 4,027 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. F3 · derivative.exercise_date: On August 27, 2010, Reporting Person was granted an option to purchase 200,000 shares of the common stock of Old Vaxart under the Plan at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 4,027 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 2,014 | Not disclosed Strike: $6.49 | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · derivative · entry 4 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,014 Underlying: Common Stock · 2,014 shares Expires 2018-03-13 F1 · kind: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). F2 · price: On March 13, 2008, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Old Vaxart under Old Vaxart's Amended and Restated 2007 Equity Incentive Plan (the "Plan") at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 2,014 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. F2 · derivative.exercise_date: On March 13, 2008, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Old Vaxart under Old Vaxart's Amended and Restated 2007 Equity Incentive Plan (the "Plan") at an exercise price of $0.13 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 2,014 shares of the Issuer's common stock (as adjusted for the Stock Split) at a per share exercise price of $6.49 (as adjusted for the Stock Split). This option is fully vested. Read SEC document |
| February 13, 2018 Filed Feb 16, 2018 01:33 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 25,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-010567 · doc4.xml · nonDerivative · entry 3 Tucker Sean · CIK 0001652204 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By joint trust with Frances Chang and Sean Tucker Disclosed balance after: 25,388 F1 · price: Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding (the "Stock Split"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.